Pages that link to "Q36671522"
Jump to navigation
Jump to search
The following pages link to Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases (Q36671522):
Displaying 50 items.
- Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety (Q24633360) (← links)
- Developments in Intralesional Therapy for Metastatic Melanoma (Q28069615) (← links)
- Therapy of cutaneous metastases of malignant melanoma (Q30828035) (← links)
- Treatment options for limited or symptomatic metastatic melanoma (Q31161199) (← links)
- Therapy for unresectable recurrent and in-transit extremity melanoma (Q33348506) (← links)
- Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma (Q33840446) (← links)
- Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma (Q34020065) (← links)
- Current treatment of locoregional recurrence of melanoma (Q34888462) (← links)
- The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study (Q34911120) (← links)
- TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial (Q35105819) (← links)
- Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy (Q35119800) (← links)
- Targeting the tumor microenvironment to enhance antitumor immune responses (Q35176307) (← links)
- Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. (Q35201353) (← links)
- Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. (Q35231246) (← links)
- Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. (Q35603108) (← links)
- Melanoma of the head and neck (Q35989793) (← links)
- The tumour microenvironment and implications for cancer immunotherapy (Q36521830) (← links)
- Tumour-induced immune modulation of sentinel lymph nodes (Q36577550) (← links)
- Local therapy of cancer with free IL-2. (Q36585434) (← links)
- Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells (Q37028329) (← links)
- Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy (Q37628065) (← links)
- A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma (Q37665688) (← links)
- Velimogene aliplasmid (Q37724340) (← links)
- Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology (Q37725792) (← links)
- Microinvasive melanoma: cutaneous pharmacotherapeutic approaches. (Q38088212) (← links)
- Immunotherapy for the management of advanced melanoma: the next steps (Q38091675) (← links)
- Immunomodulation of malignant melanoma by contact sensitizing agents (Q38168949) (← links)
- Intra-lesional interleukin-2 therapy for in transit melanoma. (Q38181030) (← links)
- Intralesional therapy for metastatic melanoma (Q38266193) (← links)
- In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. (Q38657642) (← links)
- In situ vaccination for the treatment of cancer. (Q38727470) (← links)
- Intralesional immunotherapy as a strategy to treat melanoma (Q38742761) (← links)
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma (Q38781322) (← links)
- Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy (Q38988662) (← links)
- Intralesional treatment of metastatic melanoma: a review of therapeutic options (Q39081034) (← links)
- Treatment of cutaneous melanoma: current approaches and future prospects. (Q39801051) (← links)
- Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. (Q39899988) (← links)
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study (Q41740586) (← links)
- Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice (Q42324447) (← links)
- Re-Inventing Intratumoral Immunotherapy for Melanoma (Q44607083) (← links)
- Limited efficacy of intratumoral IL-2 applied to large melanoma metastases (Q44853842) (← links)
- Study and treatment of locally advanced melanoma (Q44888274) (← links)
- Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). (Q45873521) (← links)
- Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma (Q46664276) (← links)
- Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. (Q48891121) (← links)
- Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity (Q49687675) (← links)
- Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma (Q50701417) (← links)
- Melanoma immunotherapy (Q56896842) (← links)
- High response rate after intratumoral treatment with interleukin-2 (Q56986750) (← links)
- Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease (Q58317803) (← links)